Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 003

Next Previous
Search
Drug Profile

B 003

Alternative Names: Anti-HER2 monoclonal antibody-MCC-DM1 conjugate; anti-HER2-MCC-DM1; B003; Recombinant anti-HER2 humanized monoclonal antibody conjugate

Latest Information Update: 27 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HER2 positive breast cancer

Most Recent Events

  • 13 Jan 2023 Shanghai Pharmaceuticals Holding completes a phase I trial for Breast cancer (Recurrent, Metastatic disease, Second line therapy or greater) in China (NCT03953833)
  • 25 Apr 2022 Phase-II clinical trials in HER2-positive-breast-cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (Shanghai Pharmaceuticals pipeline, April 2022)
  • 17 May 2019 Shanghai Pharmaceuticals Holding plans a phase I trial for Breast cancer (Recurrent, Metastatic disease, Second line therapy or greater) in May 2018 (NCT03953833)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top